Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
Printer Friendly Page IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Clinicaltrials.gov identifier:
NCT03693378


Study Contact Information:

For additional information, please contact: Cindy Callahan, RN by email or Susanne Glantz by email.

 


 


A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

About the Study

This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.

ENROLLMENT HAS CLOSED FOR THIS STUDY!

Type of Study

This study will enroll people who do not have pancreatic cancer, but have a higher risk of developing the disease. This is a study, which will watch participants for development of pancreatic cancer over time.

What the Study Entails

  • Participants will have blood samples taken and tested using the IMMray PanCan-d test.
  • Participants will also undergo imaging and doctors visits consistent with the research site's pancreatic cancer screening program.
  • The analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging assessments performed as part of standard of care pancreatic screening surveillance.
  • Any subject who shows evidence of disease while on-study will be removed from the study to receive standard of care per the hospital's guidelines.

Study Sites

United States

  • Connecticut
    • New Haven, CT: Yale University
  • Illinois
    • Chicago, IL: University of Chicago Medical Center
  • Massachusetts
    • Boston, MA: Massachusetts General Hospital
    • Worcester, MA: University of Massachusetts 
      • Contact: Giles Whalen by email        
  • New York
    • New York, NY: New York University Hospital
    • New York, NY: Columbia University   
      • Contact: Fay Kastrinos, MD by email         
    • New York, NY: Mount Sinai Hospital
  • Oregon
    • Portland, OR: Oregon Health & Science University
      • Contact: Brett Sheppard by email      
  • Pennsylvania
    • Philadelphia, PA: University of Pennsylvania
    • Pittsburgh, PA: University of Pittsburgh Medical Center
    • Contact: Randall Brand by email   

Canada

  • Quebec
    • Montreal: The Research Institute of the McGill University Health Centre

Other international sites are open in the following countries:

  • Spain
  • Sweden
  • United Kingdom     

Principal Investigator

Study Director: Rolf Ehrnström Immunovia, Inc.

This Study is Open To:

ENROLLMENT HAS CLOSED FOR THIS STUDY!

See study listing on clinicaltrials.gov

This Study is Not Open To: